Oncolytics Biotech Inc

TSX:ONCCanadaView on NASDAQ

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Contact Information

Headquarters

1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7CALGARY, AB, Canada T2R 0C5

Phone

403-670-7377

Fax

403-283-0858

Executives

Chairman of the Board, Interim Chief Executive Officer

Wayne Pisano

Chief Financial Officer

Kirk Look

Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.

Andrew Guttadauro

Vice President - Product Development

Allison Hagerman

Chief Medical Officer of Oncolytics Biotech (U.S.)

Thomas Heineman